# A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma

> **NCT00272415** · PHASE1 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 39 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** INO-1001
- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT00272415
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2009-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00272415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00272415, "A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00272415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*